These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 24156389)

  • 1. Phase I drug-interaction study of effects of calcium and magnesium infusions on oxaliplatin pharmacokinetics and acute neurotoxicity in colorectal cancer patients.
    Han CH; Khwaounjoo P; Kilfoyle DH; Hill A; McKeage MJ
    BMC Cancer; 2013 Oct; 13():495. PubMed ID: 24156389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients.
    Knijn N; Tol J; Koopman M; Werter MJ; Imholz AL; Valster FA; Mol L; Vincent AD; Teerenstra S; Punt CJ
    Eur J Cancer; 2011 Feb; 47(3):369-74. PubMed ID: 21067912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Reduction of oxaliplatin-related neurotoxicity by calcium and magnesium infusions].
    Muto O; Ando H; Ono T; Itagaki H; Kobayashi Y; Onuki M; Akashi T; Tanaka Y; Hanaoka T
    Gan To Kagaku Ryoho; 2007 Apr; 34(4):579-81. PubMed ID: 17431344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability.
    Hill A; Bergin P; Hanning F; Thompson P; Findlay M; Damianovich D; McKeage MJ
    BMC Cancer; 2010 Aug; 10():451. PubMed ID: 20731872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage II/III colorectal cancer.
    Wang DS; Wang ZQ; Chen G; Peng JW; Wang W; Deng YH; Wang FH; Zhang JW; Liang HL; Feng F; Xie CB; Ren C; Jin Y; Shi SM; Fan WH; Lu ZH; Ding PR; Wang F; Xu RH; Li YH
    Cancer Med; 2020 Jan; 9(1):151-159. PubMed ID: 31724334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: a prospective randomized study.
    Ishibashi K; Okada N; Miyazaki T; Sano M; Ishida H
    Int J Clin Oncol; 2010 Feb; 15(1):82-7. PubMed ID: 20108160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ca/Mg infusions for the prevention of oxaliplatin-related neurotoxicity in patients with colorectal cancer: a meta-analysis.
    Wen F; Zhou Y; Wang W; Hu QC; Liu YT; Zhang PF; Du ZD; Dai J; Li Q
    Ann Oncol; 2013 Jan; 24(1):171-8. PubMed ID: 22898039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance).
    Loprinzi CL; Qin R; Dakhil SR; Fehrenbacher L; Flynn KA; Atherton P; Seisler D; Qamar R; Lewis GC; Grothey A
    J Clin Oncol; 2014 Apr; 32(10):997-1005. PubMed ID: 24297951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
    Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
    Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity.
    Milla P; Airoldi M; Weber G; Drescher A; Jaehde U; Cattel L
    Anticancer Drugs; 2009 Jun; 20(5):396-402. PubMed ID: 19287306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer.
    Gamelin L; Boisdron-Celle M; Delva R; Guérin-Meyer V; Ifrah N; Morel A; Gamelin E
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4055-61. PubMed ID: 15217938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of calcium/ magnesium infusion in oxaliplatin-based chemotherapy for colorectal cancer patients.
    Kurniali PC; Luo LG; Weitberg AB
    Oncology (Williston Park); 2010 Mar; 24(3):289-92. PubMed ID: 20394142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy.
    Chay WY; Tan SH; Lo YL; Ong SY; Ng HC; Gao F; Koo WH; Choo SP
    Asia Pac J Clin Oncol; 2010 Dec; 6(4):270-7. PubMed ID: 21114776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT.
    Hochster HS; Grothey A; Hart L; Rowland K; Ansari R; Alberts S; Chowhan N; Ramanathan RK; Keaton M; Hainsworth JD; Childs BH
    Ann Oncol; 2014 Jun; 25(6):1172-8. PubMed ID: 24608198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study.
    Oki E; Emi Y; Kojima H; Higashijima J; Kato T; Miyake Y; Kon M; Ogata Y; Takahashi K; Ishida H; Saeki H; Sakaguchi Y; Yamanaka T; Kono T; Tomita N; Baba H; Shirabe K; Kakeji Y; Maehara Y
    Int J Clin Oncol; 2015 Aug; 20(4):767-75. PubMed ID: 25627820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7.
    Grothey A; Nikcevich DA; Sloan JA; Kugler JW; Silberstein PT; Dentchev T; Wender DB; Novotny PJ; Chitaley U; Alberts SR; Loprinzi CL
    J Clin Oncol; 2011 Feb; 29(4):421-7. PubMed ID: 21189381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double‑blind, placebo‑controlled trial of goshajinkigan to prevent oxaliplatin‑induced neuropathy.
    Kono T; Hata T; Morita S; Munemoto Y; Matsui T; Kojima H; Takemoto H; Fukunaga M; Nagata N; Shimada M; Sakamoto J; Mishima H
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1283-90. PubMed ID: 24121454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute oxaliplatin-induced peripheral nerve hyperexcitability.
    Wilson RH; Lehky T; Thomas RR; Quinn MG; Floeter MK; Grem JL
    J Clin Oncol; 2002 Apr; 20(7):1767-74. PubMed ID: 11919233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
    Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
    JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxaliplatin treatment and peripheral nerve damage in cancer patients: A Polish cohort study.
    Banach M; Zygulska AL; Krzemieniecki K
    J Cancer Res Ther; 2018; 14(5):1010-1013. PubMed ID: 30197340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.